Research programme: induced pluripotent stem cell therapies - Creative Medical Technology Holdings/Greenstone Biosciences
Alternative Names: iPScelz™Latest Information Update: 15 Mar 2023
At a glance
- Originator Creative Medical Technology Holdings; Greenstone Biosciences
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Mar 2023 Preclinical trials in Unspecified in USA (Parenteral) (Creative Medical Technology Holdings pipeline, March 2023)
- 15 Jun 2022 Creative Medical Technology Holdings in-licenses the ImmCelz® technology from Jadi Cell, prior to June 2022 (Creative Medical Technology Holdings pipeline, July 2022)
- 15 Jun 2022 Creative Medical Technology Holdings and Greenstone Biosciences agree to co-develop induced pluripotent stem cell (iPSC) therapies